Bug-brain axis

Why Axial is targeting the gut microbiome to treat CNS disorders

By Emily Cukier-Meisner | Dec 2, 2016 | 10:59 PM GMT

Investors supplied Axial Biotherapeutics Inc. with enough cash to get human proof of concept showing that correcting microbiome imbalances can treat pathologies and symptoms of neurological disorders.

The newco debuted Nov. 30 with a $19.2 million series A co-led by Longwood Fund and

Read the full 425 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE